Avodart and Levothyroxine Interaction: What Patients and Clinicians Need to Know

What Is the Actual Interaction Between Dutasteride and Levothyroxine?

No established direct pharmacokinetic interaction exists between dutasteride and levothyroxine in peer-reviewed literature or the FDA-approved prescribing information for either agent. The interaction risk is indirect and context-dependent. Dutasteride does not bind the thyroid hormone receptor, and levothyroxine does not inhibit CYP3A4 or CYP3A5, the two enzymes that clear dutasteride. Patients taking both drugs together are generally safe, provided levothyroxine is taken correctly on an empty stomach and the two medications are not lumped into a single morning pill pile with agents known to block thyroid hormone absorption.

Why the Question Comes Up at All

Many men taking dutasteride for benign prostatic hyperplasia (BPH) or off-label for androgenetic alopecia are middle-aged or older, a population with a 10 to 15 percent prevalence of hypothyroidism requiring levothyroxine replacement [1]. These patients naturally ask their prescribers whether two drugs taken for separate conditions can interfere. The short answer is that dutasteride itself is not an absorptive antagonist of levothyroxine, but the broader context of polypharmacy in this patient group creates real clinical risk.

The Real Absorption Risk in Polypharmacy

Levothyroxine absorption ranges from 60 to 80 percent under ideal fasting conditions and drops sharply when taken alongside calcium carbonate, ferrous sulfate, proton pump inhibitors, cholestyramine, or antacids containing aluminum [2]. Men with BPH who also take dutasteride frequently take one or more of these agents. The clinical mistake is not the dutasteride itself but the concurrent calcium supplement or the morning omeprazole taken at the same time as the levothyroxine.

How Dutasteride Is Metabolized: CYP3A4 and CYP3A5

Dutasteride is extensively metabolized by CYP3A4 and CYP3A5 in the liver to four identified metabolites, three of which (4-hydroxydutasteride, 1,2-dihydrodutasteride, and 6-hydroxydutasteride) retain some 5-alpha reductase inhibitory activity [3]. The FDA label for Avodart (GlaxoSmithKline, revised 2022) states that strong CYP3A4 inhibitors such as ritonavir, ketoconazole, and verapamil can raise dutasteride plasma concentrations significantly, and dose adjustment or careful monitoring may be warranted in those combinations.

Levothyroxine and CYP Enzymes

Levothyroxine (T4) is not a substrate, inhibitor, or inducer of the CYP450 system in any clinically meaningful way at therapeutic doses. It is converted peripherally to triiodothyronine (T3) primarily by deiodinase enzymes (DIO1, DIO2) in the liver, kidney, and skeletal muscle, not by cytochrome P450 oxidases [4]. This means dutasteride's CYP3A4-dependent clearance pathway and levothyroxine's deiodinase-dependent activation pathway operate on entirely separate enzymatic tracks.

P-glycoprotein and Transport Proteins

Dutasteride is not a known substrate or inhibitor of P-glycoprotein (P-gp) or the organic anion transporting polypeptides (OATPs) at concentrations achieved with the standard 0.5 mg daily dose [3]. Levothyroxine distributes primarily bound to thyroxine-binding globulin, transthyretin, and albumin, and its intestinal transport involves MCT8 and OATP1A2 rather than P-gp [5]. No mechanistic basis exists for dutasteride to alter levothyroxine transport or protein binding at standard therapeutic exposures.

Severity Rating and DDI Database Classifications

Using the standard Lexi-Interact / Micromedex tiered framework adapted for clinical practice, the dutasteride-levothyroxine pairing falls into the following category:

| DDI Database | Severity Rating | Confidence | Action Required | |---|---|---|---| | Lexi-Interact | Not classified / no interaction listed | N/A | Routine monitoring | | Micromedex | No interaction documented | N/A | No special precaution | | FDA label (dutasteride) | No mention of levothyroxine | N/A | Standard counseling | | FDA label (levothyroxine) | Broad absorption warnings | Moderate | Timing separation |

The American Thyroid Association (ATA) 2014 guidelines on hypothyroidism management note that "many drugs and dietary supplements can interfere with levothyroxine absorption or metabolism," and list specific agents by category, none of which include 5-alpha reductase inhibitors [6]. This absence is clinically meaningful. It means the interaction, if any, has not risen to a signal that warranted inclusion in major society guidelines after decades of co-prescribing.

Pharmacodynamic Considerations: Do the Two Drugs Work Against Each Other?

Dutasteride inhibits both type 1 and type 2 5-alpha reductase isoforms, blocking conversion of testosterone to dihydrotestosterone (DHT). Levothyroxine replaces or supplements endogenous thyroxine in patients with primary or central hypothyroidism. These mechanisms operate on different receptor families (nuclear androgen receptor versus thyroid hormone receptor alpha and beta) and different target tissues, with no identified cross-talk at the receptor level.

Sex Hormone-Binding Globulin: A Subtle Consideration

Thyroid hormone status does influence sex hormone-binding globulin (SHBG) levels. Hypothyroidism lowers SHBG, and replacing thyroid hormone with levothyroxine typically raises SHBG back toward normal [7]. Higher SHBG binds more free testosterone, which could theoretically alter the substrate pool available for 5-alpha reduction by the enzyme dutasteride is inhibiting. This effect is pharmacodynamically minor: dutasteride produces greater than 90 percent suppression of serum DHT within 1 to 2 weeks of starting therapy [3], leaving essentially no 5-alpha reductase activity to be modulated by small shifts in free testosterone.

Testosterone and Thyroid Hormone Cross-Talk

In men taking testosterone replacement therapy alongside dutasteride, the addition of levothyroxine for co-existing hypothyroidism requires attention to total free testosterone interpretation, because SHBG changes after levothyroxine initiation can shift the free versus total testosterone ratio without changing total testosterone [7]. This is a monitoring nuance, not an interaction requiring dose adjustment of dutasteride.

Levothyroxine Absorption: The Clinical Priority

Getting levothyroxine timing right matters far more than worrying about dutasteride. The ATA guidelines specify that levothyroxine should be taken on an empty stomach, 30 to 60 minutes before breakfast, or alternatively 3 to 4 hours after the last evening meal [6]. Administering the tablet with coffee, dairy products, or high-fiber foods reduces bioavailability meaningfully.

Agents That Definitively Reduce Levothyroxine Absorption

The following agents have documented reduction in levothyroxine bioavailability and require either dose separation or TSH re-evaluation [2, 6]:

• Calcium carbonate: reduces absorption by up to 25 percent; separate by at least 4 hours
• Ferrous sulfate: reduces absorption by approximately 30 percent; separate by at least 4 hours
• Cholestyramine and colestipol: separate by at least 4 to 6 hours
• Aluminum- and magnesium-containing antacids: separate by at least 4 hours
• Proton pump inhibitors (omeprazole, esomeprazole, pantoprazole): reduce absorption by altering gastric pH; consider switching levothyroxine to liquid formulation or softgel capsule (Tirosint)
• Sucralfate: separate by at least 2 hours
• Sevelamer: separate by at least 4 hours

Dutasteride is not on this list and does not reduce gastric pH, chelate levothyroxine, or bind bile acids.

Levothyroxine Formulation and Absorption Consistency

Liquid levothyroxine (Tirosint-SOL) and softgel capsule formulations (Tirosint) are less sensitive to gastric pH and may be taken with food in patients who cannot reliably fast [8]. A 2013 study published in the Journal of Clinical Endocrinology and Metabolism (N=45) found that softgel levothyroxine produced significantly better TSH normalization than standard tablets in patients with gastric malabsorption syndromes [8]. Patients on dutasteride who also use PPIs chronically should discuss formulation switching with their prescribing clinician.

Clinical Monitoring Protocol When Both Drugs Are Prescribed

TSH Targets and Testing Schedule

The ATA recommends a TSH target of 0.5 to 2.5 mIU/L for most adults under 65 with primary hypothyroidism, with a slightly broader range of 1.0 to 4.0 mIU/L acceptable for patients over 65 [6]. When a patient is stable on both dutasteride and levothyroxine, annual TSH monitoring is reasonable. Any change in the medication regimen, body weight exceeding 10 percent, pregnancy, or new symptoms (fatigue, cold intolerance, constipation, weight gain, bradycardia) warrants retesting within 6 to 8 weeks.

PSA Interpretation in Patients on Both Drugs

Dutasteride reduces serum prostate-specific antigen (PSA) by approximately 50 percent after 6 months of therapy [3]. Clinicians monitoring PSA for prostate cancer screening in men taking both dutasteride and levothyroxine should double the measured PSA value when comparing to age-appropriate reference ranges, per FDA label guidance. Hypothyroidism itself has not been shown to alter PSA in a clinically meaningful way, so levothyroxine therapy does not complicate PSA interpretation beyond the standard dutasteride adjustment.

DHT Monitoring

Dutasteride suppresses serum DHT by more than 90 percent at the standard 0.5 mg daily dose [3]. Routine DHT monitoring is not required for BPH management but is used in some clinical hair loss protocols to confirm adequate enzyme inhibition. TSH levels do not affect DHT measurement validity.

Patient Counseling Points

Clear instruction reduces adherence failures more than most drug adjustments. When counseling a patient taking both dutasteride and levothyroxine, these are the points that matter most:

Timing. Take levothyroxine first thing in the morning on an empty stomach. Dutasteride can be taken at any time of day with or without food, so afternoon or evening dosing separates it completely from the levothyroxine window.

Pill sorting matters. Patients who use weekly pill organizers sometimes mix levothyroxine with calcium supplements or antacids into the same daily compartment. This is the most common cause of subtherapeutic levothyroxine levels in otherwise adherent patients.

Symptom awareness. Patients should know that unexplained fatigue, constipation, weight gain of more than 2 to 3 kilograms, cold intolerance, or depressed mood may signal undertreated hypothyroidism and warrant a TSH check, not just reassurance.

Dutasteride's long half-life. At roughly 5 weeks, dutasteride accumulates slowly and declines slowly [3]. Missing a few doses will not cause acute DHT rebound, but patients should be counseled not to double up doses after a miss.

Sexual side effects are drug-specific. Dutasteride carries a labeled risk of decreased libido, ejaculatory dysfunction, and gynecomastia in a small percentage of patients (approximately 1 to 2 percent in the COMBAT trial at 4 years) [9]. Undertreated hypothyroidism also reduces libido and can cause erectile dysfunction. Distinguishing which drug or which condition is responsible requires a TSH check, not empirical dose changes of dutasteride.

Special Populations

Older Adults

Men over 65 taking dutasteride for BPH are more likely to have co-existing hypothyroidism, more likely to be on multiple interacting drugs (calcium, PPIs, iron), and more likely to show atypical hypothyroid symptoms (cognitive slowing, falls, constipation misattributed to BPH medications). Annual TSH screening in this cohort is warranted even without specific levothyroxine-dutasteride concern.

Patients on Testosterone Replacement Therapy

Some men use dutasteride alongside testosterone replacement therapy (TRT) to blunt DHT-mediated prostate growth and scalp miniaturization while also taking levothyroxine for hypothyroidism. In this three-drug regimen, the principal monitoring priorities are free testosterone, TSH, hematocrit, and PSA (with the PSA doubling adjustment). Adding levothyroxine does not require changing the dutasteride dose, but an SHBG recheck 8 to 12 weeks after achieving euthyroidism allows accurate free testosterone interpretation.

Women Taking Dutasteride Off-Label

Dutasteride is used off-label in postmenopausal women for pattern hair loss. Postmenopausal women have a higher prevalence of Hashimoto thyroiditis and hypothyroidism than age-matched men [1]. The same timing separation principle applies: levothyroxine in the morning on an empty stomach, dutasteride at any other convenient time.

What the FDA Labels Say

The FDA-approved prescribing information for Avodart (revised June 2022) lists the following clinically significant drug interactions: CYP3A4 inhibitors (verapamil, diltiazem, cimetidine, ciprofloxacin, ketoconazole, ritonavir) that may increase dutasteride plasma concentrations, and alpha-adrenergic blockers (tamsulosin, doxazosin) used in combination for BPH [3]. Levothyroxine does not appear on any interaction list in the Avodart label.

The FDA-approved prescribing information for levothyroxine sodium tablets lists more than 20 drug classes affecting absorption or metabolism, including antacids, bile acid sequestrants, calcium supplements, iron salts, proton pump inhibitors, sucralfate, and several anticonvulsants [2]. 5-alpha reductase inhibitors are not listed in the levothyroxine label either.

The absence of a listed interaction between these two specific agents in both FDA labels, combined with the distinct metabolic pathways described above, supports the clinical conclusion that this combination is safe with appropriate monitoring.

Summary of the Evidence Base

The body of evidence on this specific drug pair is defined largely by what is absent: no published pharmacokinetic interaction study, no signal in the FDA Adverse Event Reporting System (FAERS) sufficient to prompt a label update, and no mention in major endocrinology or urology society guidelines. This absence across multiple independent regulatory and clinical sources is informative. Clinicians seeing a patient on both drugs can apply standard levothyroxine counseling (timing, absorption interference from other agents, TSH monitoring) without dutasteride-specific modification.

The REDUCE trial (N=6,729, 4-year follow-up) evaluated dutasteride 0.5 mg daily for prostate cancer risk reduction and collected extensive safety and laboratory data [10]. No thyroid-related adverse events were identified as statistically more frequent in the dutasteride arm versus placebo, providing indirect population-level evidence that long-term dutasteride does not disrupt thyroid function.